EcoDrugPlus

Cyclin Dependent Kinase 6

Ensembl ID : ENSRROG00000030049
Gene Symbol: CDK6
4 Cross references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cyclin Dependent Kinase 7

Ensembl ID : ENSRROG00000040620
Gene Symbol: CDK7
4 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cyclin Dependent Kinase 9

Ensembl ID : ENSRROG00000040845
Gene Symbol: CDK9
4 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cysteinyl Leukotriene Receptor 1

Ensembl ID : ENSRROG00000003369
Gene Symbol: CYSLTR1
4 Cross references
177 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytidine Deaminase

Ensembl ID : ENSRROG00000029546
Gene Symbol: CDA
4 Cross references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 11b1, Mitochondrial

Ensembl ID : ENSRROG00000037768
Gene Symbol: LOC104679773
3 Cross references
33 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 11b2, Mitochondrial

Ensembl ID : ENSRROG00000045697
Gene Symbol: LOC104679775
2 Cross references
36 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 3a7-Like

Ensembl ID : ENSRROG00000042643
Gene Symbol: LOC104672097
2 Cross references
643 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 17 Subfamily A Member 1

Ensembl ID : ENSRROG00000039877
Gene Symbol: CYP17A1
4 Cross references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSRROG00000027796
Gene Symbol: CYP19A1
4 Cross references
315 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 26 Subfamily A Member 1

Ensembl ID : ENSRROG00000042373
Gene Symbol: CYP26A1
4 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 3 Subfamily A Member 4

Ensembl ID : ENSRROG00000030854
Gene Symbol: CYP3A4
4 Cross references
637 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).